- Home
- MBC vs ARQT Comparison
MBC vs ARQT Comparison
Compare MBC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- ARQT
- Stock Information
- Founded
- MBC 1954
- ARQT 2016
- Country
- MBC United States
- ARQT United States
- Employees
- MBC N/A
- ARQT N/A
- Industry
- MBC Agricultural Chemicals
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- MBC Industrials
- ARQT Health Care
- Exchange
- MBC Nasdaq
- ARQT Nasdaq
- Market Cap
- MBC 1.5B
- ARQT 1.7B
- IPO Year
- MBC N/A
- ARQT 2020
- Fundamental
- Price
- MBC $11.11
- ARQT $13.63
- Analyst Decision
- MBC Strong Buy
- ARQT Strong Buy
- Analyst Count
- MBC 1
- ARQT 6
- Target Price
- MBC $15.00
- ARQT $18.80
- AVG Volume (30 Days)
- MBC 1.2M
- ARQT 1.9M
- Earning Date
- MBC 05-06-2025
- ARQT 05-06-2025
- Dividend Yield
- MBC N/A
- ARQT N/A
- EPS Growth
- MBC N/A
- ARQT N/A
- EPS
- MBC 0.77
- ARQT N/A
- Revenue
- MBC $2,722,600,000.00
- ARQT $212,819,000.00
- Revenue This Year
- MBC $2.24
- ARQT $61.42
- Revenue Next Year
- MBC $3.69
- ARQT $37.91
- P/E Ratio
- MBC $14.39
- ARQT N/A
- Revenue Growth
- MBC 1.30
- ARQT 100.03
- 52 Week Low
- MBC $10.07
- ARQT $6.99
- 52 Week High
- MBC $20.67
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- MBC 45.04
- ARQT 44.68
- Support Level
- MBC $9.78
- ARQT $13.15
- Resistance Level
- MBC $11.45
- ARQT $14.61
- Average True Range (ATR)
- MBC 0.50
- ARQT 0.89
- MACD
- MBC 0.00
- ARQT -0.07
- Stochastic Oscillator
- MBC 48.36
- ARQT 37.23
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.